The average price point forecasted by analysts for CRISPR Therapeutics AG (CRSP) is $87.78, which is $15.6 above the current market price. The public float for CRSP is 76.26M, and currently, short sellers hold a 18.21% ratio of that floaft. The average trading volume of CRSP on November 21, 2023 was 1.50M shares.

CRSP) stock’s latest price update

CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has surge by 6.32relation to previous closing price of 67.89. Nevertheless, the company has seen a 38.78% surge in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-18 that Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare genetic diseases.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


CRSP’s Market Performance

CRISPR Therapeutics AG (CRSP) has experienced a 38.78% rise in stock performance for the past week, with a 81.45% rise in the past month, and a 50.59% rise in the past quarter. The volatility ratio for the week is 8.95%, and the volatility levels for the past 30 days are at 8.33% for CRSP. The simple moving average for the past 20 days is 47.75% for CRSP’s stock, with a 39.80% simple moving average for the past 200 days.

CRSP Trading at 54.02% from the 50-Day Moving Average

After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.25% of gains for the given period.

Volatility was left at 8.33%, however, over the last 30 days, the volatility rate increased by 8.95%, as shares surge +86.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.53% upper at present.

During the last 5 trading sessions, CRSP rose by +38.78%, which changed the moving average for the period of 200-days by +28.62% in comparison to the 20-day moving average, which settled at $50.53. In addition, CRISPR Therapeutics AG saw 77.56% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRSP starting from Kulkarni Samarth, who sale 25,000 shares at the price of $64.88 back on May 30. After this action, Kulkarni Samarth now owns 387,377 shares of CRISPR Therapeutics AG, valued at $1,621,894 using the latest closing price.

Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 25,000 shares at $50.67 during a trade that took place back on Apr 25, which means that Kulkarni Samarth is holding 387,377 shares at $1,266,638 based on the most recent closing price.

Stock Fundamentals for CRSP

Current profitability levels for the company are sitting at:

The net margin for CRISPR Therapeutics AG stands at -54271.70. The total capital return value is set at -28.38, while invested capital returns managed to touch -27.57. Equity return is now at value -19.20, with -15.92 for asset returns.

Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 13.01 points at debt to equity in total, while total debt to capital is 11.51. Total debt to assets is 10.88, with long-term debt to equity ratio resting at 12.17. Finally, the long-term debt to capital ratio is 10.77.

When we switch over and look at the enterprise to sales, we see a ratio of 22.48, with the company’s debt to enterprise value settled at 0.15. The receivables turnover for the company is 0.12 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.30.


In a nutshell, CRISPR Therapeutics AG (CRSP) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.